Beijing Avistone Biotechnology Co. Ltd. has obtained IND clearance from the FDA for ANS-03, a next-generation tyrosine kinase inhibitor (TKI) targeting both ROS proto-oncogene 1 (ROS1) and neurotrophic tropomyosin receptor kinase (NTRK).
Researchers from Northwestern University and Yale University have presented new preclinical data for KL-50, a small molecule under investigation for the treatment of glioblastoma. KL-50 was designed to fluoro-ethylate DNA bases, resulting in DNA inter-strand cross-links and subsequent DNA damage that triggers DNA mismatch repair (MMR)-independent apoptosis.
Elevar Therapeutics Inc. will license Relay Therapeutics Inc.’s “NDA-ready” bile duct cancer therapy, lirafugratinib (RLY-4008), through a potential $500 million deal as Elevar, an HLB Co. Ltd. subsidiary, seeks to diversify its oncology portfolio following the U.S. FDA rejection of its liver cancer drug candidate in May.
Duality Biologics is out-licensing preclinical antibody-drug conjugate (ADC) candidate DB-1324 under an option agreement with GSK plc potentially worth more than $1 billion.
Takeda Pharmaceutical Co. Ltd. is licensing Keros Therapeutics Inc.’s activin inhibitor elritercept in a global development and commercialization deal worth up to $1.3 billion that excludes mainland China, Hong Kong and Macau.
Bladder cancer is a challenging disease that poses significant risks to patients, often leading to a grim prognosis. Recent research has brought attention to chaperonin-containing tailless complex polypeptide 1 subunit 3 (CCT3), identified as an oncogene in multiple tumor types. However, its specific role in bladder cancer remains largely unexplored.
Benobio Co. Ltd. has discovered new benzothiophene derivatives acting as bromodomain-containing protein 2 (BD1 domain) (Brd2 BD1) inhibitors reported to be useful for the treatment of cancer.
Elgen Therapeutics Inc. has patented new 4-chromanone derivative proteolysis targeting chimera (PROTAC) compounds comprising a von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled with a WD repeat-containing protein 5 (WDR5; BIG3)-targeting moiety through a linker.
Work at Tango Therapeutics Inc. has led to the identification of new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
RSS
